Department of Cardiology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100700, China; Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, 55902, United States.
Internal Medicine Division, Tieying Hospital of Fengtai District, Beijing, 100078, China.
Complement Ther Med. 2021 Mar;57:102643. doi: 10.1016/j.ctim.2020.102643. Epub 2020 Dec 15.
Yoga has been widely practiced and has recently shown benefits in patients with coronary heart disease (CHD), however, evidence is inconsistent.
We conducted a systematic review and meta-analysis by searching PubMed/Medline, the Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE and Web of Science from inception to May 31, 2020 for randomised controlled trials (RCTs) comparing yoga with usual care or non-pharmacological interventions in patients with CHD. The primary outcomes were all-cause mortality and health related quality of life (HR-QoL). Secondary outcomes were a composite cardiovascular outcome, exercise capacity and cardiovascular risk factors (blood pressure, lipid profiles and body mass index).
Seven RCTs with a total of 4671 participants were included. Six RCTs compared yoga with usual care and one compared yoga with designed exercise. The mean age of the participants ranged from 51.0-60.7 years and the majority of them were men (85.4 %). Pooled results showed that compared with usual care, yoga had no effect on all-cause mortality (RR, 1.02; 95 % CI, 0.75-1.39), but it significantly improved HR-QoL (SMD, 0.07; 95 % CI, 0.01 - 0.14). A non-significant reduction of the composite cardiovascular outcome was observed (133 vs. 154; RR, 0.63; 95 % CI, 0.15-2.59). Serum level of triglyceride and high density lipoprotein cholesterol, blood pressure and body mass index were also significantly improved. The study comparing yoga with control exercise also reported significantly better effects of yoga on HR-QoL (85.75 vs. 75.24, P < 0.001). No severe adverse events related to yoga were reported.
Yoga might be a promising alternative for patients with CHD as it is associated with improved quality of life, less number of composite cardiovascular events, and improved cardiovascular risk factors.
瑜伽在冠心病(CHD)患者中得到了广泛应用,并且最近显示出了益处,但证据并不一致。
我们检索了 PubMed/Medline、Cochrane 中央对照试验注册库(CENTRAL)、EMBASE 和 Web of Science,从建库至 2020 年 5 月 31 日,以查找比较瑜伽与常规护理或非药物干预在 CHD 患者中的随机对照试验(RCT),对其进行了系统评价和荟萃分析。主要结局是全因死亡率和健康相关生活质量(HR-QoL)。次要结局是心血管复合结局、运动能力和心血管危险因素(血压、血脂谱和体重指数)。
纳入了 7 项 RCT,共 4671 名参与者。6 项 RCT 比较了瑜伽与常规护理,1 项比较了瑜伽与设计的运动。参与者的平均年龄为 51.0-60.7 岁,其中大多数为男性(85.4%)。汇总结果显示,与常规护理相比,瑜伽对全因死亡率无影响(RR,1.02;95%CI,0.75-1.39),但显著改善了 HR-QoL(SMD,0.07;95%CI,0.01-0.14)。观察到心血管复合结局的非显著降低(133 例比 154 例;RR,0.63;95%CI,0.15-2.59)。血清甘油三酯和高密度脂蛋白胆固醇水平、血压和体重指数也显著改善。比较瑜伽与对照运动的研究还报告称,瑜伽对 HR-QoL 的改善效果明显更好(85.75 比 75.24,P<0.001)。没有报告与瑜伽相关的严重不良事件。
瑜伽可能是 CHD 患者的一种有前途的替代疗法,因为它与改善生活质量、减少心血管复合事件以及改善心血管危险因素有关。